ArticleJMIR cancer2026
Predicting Overall Survival in Patients With Multiple Primary Lung Cancer: Nomogram Development and Validation Study.
Article in JMIR cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Paired Inter-Lesion Invasiveness and Recurrence Risk in Synchronous Multiple Primary Lung Adenocarcinoma: Focus on the IAC-Dominant Subgroup.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: With the rapid development of medical technology and the emphasis on early lung cancer screening, the detection rate of multiple primary lung cancer (MPLC) has increased in recent years. However, the prognostic determinants and clinical characteristics of patients with MPLC remain poorly characterized. Objective: This study aimed to develop and validate a nomogram for predicting overall survival (OS) in patients with MPLC using data from the Surveillance, Epidemiology, and End Results database. Methods: This study was reported in accordance with the TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) guidelines. A cohort of 4177 patients with MPLC (2007-2015) was obtained from the Surveillance, Epidemiology, and End Results database. The patients were randomly divided into training (n=2923) and validation (n=1254) cohorts at a 7:3 ratio. Backward stepwise Cox regression identified 11 independent risk factors, which were integrated into a nomogram predicting 3-, 5-, and 8-year OS rates. Results: The nomogram demonstrated superior discriminative ability compared to the American Joint Committee on Cancer staging system, with higher area under the receiver operating characteristic curve values for 3-, 5-, and 8-year OS predictions in both cohorts (training cohort: 0.743, 0.751, and 0.759, respectively; validation cohort: 0.737, 0.734, and 0.695, respectively). Calibration curves and decision curve analysis confirmed its clinical utility. Conclusions: This study establishes a validated nomogram incorporating clinical and socioeconomic variables to optimize prognostic assessment and personalized treatment planning for patients with MPLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.